Changes of gut microbiota during silybin mediated treatment of high-fat diet-induced nonalcoholic fatty liver diseasein mouse.
Gut microbiota involved in pathogenesis of nonalcoholic fatty liver disease (NAFLD). Silybin (Sil), a naturally occurring hepatoprotective agent, was widely used for treating NAFLD. Whether Sil effects gut microbiota during its actions in treating NAFLD, which is unknown. We aimed to examine the effect of Sil on intestinal flora dysbiosis induced by high-fat diet (HFD). After 10 weeks of feeding normal chow diet (NCD) or HFD, mice were given daily by gavage for 8 weeks. Cecal contents were harvested for study of short chain fatty acids (SCFAs), bile acids and gut microbiota alteration. Sil showed protective effects against dietary-induced obesity and liver steatosis, accordingly gut microbiota composition changed. At phylum level, compared with HFD group, mice in the Sil-treated group had significant lower level of Firmicutes and the ratio of Firmicutes to Bacteroidetes (P<0.05). At genus level, Sil-treated group have significant lower level of Lachnoclostridium, Lachnospiraceae_UCG-006 and Mollicutes_RF9, which were reported to be potentially related to diet-induced obesity, and increased levels of Blautia (P<0.05), Akkermansia (P<0.05), Bacteroides(P<0.05) which were known to have beneficial effect on improving NAFLD. Sil also showed inhibitory effect on well-known beneficial bacteria, such as Alloprevotella, Lactobacillus. Moreover, production of acetate, propionate and butyrate increased, while generation of formate and conversion of cytotoxic secondary metabolites (LCA, DCA) decreased in mice treated with Sil. Sil might have beneficial effects on ameliorating NAFLD and mediate HFD-induced change of gut microbiota composition, followed with major changes in secondary metabolites, such as SCFAs and BAs.